Skip to main content

ImmunityBio, Inc.

corporate_fare Company Profile

ImmunityBio, Inc.

IBRX·NASDAQ·Life Sciences·CIK 0001326110

ImmunityBio, Inc. is a biotechnology company that develops and sells advanced immunotherapies designed to activate a patient's immune system for long-lasting protection against cancer and infectious diseases. The company's development platforms create biologic products and product candidates, including cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. These platforms have produced initial therapeutic agents intended for clinical trials in both liquid and solid tumors. ImmunityBio's primary biologic product candidate is Anktiva, an FDA-approved immunotherapy. Anktiva is used in combination with bacillus calmette-guérin (BCG) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer that includes carcinoma in situ, with or without papillary tumors. Another key product candidate is 3M-052, which is a synthetic TLR7/8 agonist, along with its formulations and related technology. The company collaborates with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd. It also holds license agreements with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is headquartered in San Diego, California.

ImmunityBio, Inc. (NASDAQ:IBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for IBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IBRX spans 10-Q, 8-K, SCHEDULE 13D/A, DEF 14A.

Recent high-impact activity:

  • ImmunityBio 10-Q: Q3 Revenue $48.7M, $334.3M Cash, Going-Concern Warning
  • ImmunityBio Q3 Revenue Up 53% to $48.7M; $1.0B Nine-Month Loss Is Mostly Non-Cash
  • ImmunityBio Q3 ANKTIVA Sales Jump 53% to $48.7M; Nine-Month Revenue Up 92%
  • ANKTIVA Plus BCG Hits Primary Endpoint in BCG-Naïve Bladder Cancer Trial
  • ANKTIVA Long-Term Data: 84% Avoid Cystectomy at Three Years, Responses Past 53 Months

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$113.29M
Net Income
-$351.4M
Diluted EPS
-$0.38
Op. Cash Flow
-$304.94M
Free Cash Flow
-$308.78M
Gross Profit
$112.53M
Operating Income
-$256.03M
Cash & Equivalents
$88.33M
Total Debt
$1.75M
Debt / Equity
-0.00×
Net Margin
-310.2%
Shares Outstanding
1.01B sh
Source: 10-K · filed 2026-02-23 · accession 0001326110-26-000030

Short Interest & Short Volume

10.77 days to cover

FINRA reported short interest of 126,083,790 shares in IBRX as of the October 30, 2026 settlement, a 2.6% increase from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 58.3% of IBRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)126,083,790 shares as of October 30, 2026
Change vs prior period▲ 2.6%
Days to cover10.77 at avg daily volume of 11,703,488
Daily short volume (FINRA facilities)58.3% of 4,714,489 shares on November 20, 2026
5-day average short volume63.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$6.08 +1.08% today
52-week range · as of 2026-11-09 $1.95 – $12.43
Market cap
$6.4B
Volume
10.6M (0.8× avg)
3-mo avg 14.1M
Live data · 2026-11-21 05:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $6.08 info
Change: -$1.51 (-20%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.08 info
Change: -$2.01 (-25%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.08 info
Change: -$2.76 (-31%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $6.08 info
Change: -$2.68 (-31%) info
Market Cap: $6.404B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.08 info
Change: -$3.34 (-35%) info
Market Cap: $6.404B info
IBRX
Oct 14, 2026, 11:31 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $9.74
Real-time Price: $6.08 info
Change: -$3.66 (-38%) info
Market Cap: $6.404B info
IBRX
Oct 05, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.63
Real-time Price: $6.08 info
Change: -$4.55 (-43%) info
Market Cap: $6.404B info
IBRX
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.62
Real-time Price: $6.08 info
Change: -$1.54 (-20%) info
Market Cap: $6.404B info
IBRX
Aug 06, 2026, 6:50 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $7.29
Real-time Price: $6.08 info
Change: -$1.21 (-17%) info
Market Cap: $6.404B info
IBRX
Aug 04, 2026, 7:45 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.09
Real-time Price: $6.08 info
Change: -$1.01 (-14%) info
Market Cap: $6.404B info
IBRX
Aug 04, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.18
Real-time Price: $6.08 info
Change: -$1.10 (-15%) info
Market Cap: $6.404B info
IBRX
Aug 04, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.18
Real-time Price: $6.08 info
Change: -$1.10 (-15%) info
Market Cap: $6.404B info
IBRX
Jul 29, 2026, 6:45 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $6.86
Real-time Price: $6.08 info
Change: -$0.775 (-11%) info
Market Cap: $6.404B info
IBRX
May 21, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $7.95
Real-time Price: $6.08 info
Change: -$1.87 (-23%) info
Market Cap: $6.404B info
IBRX
May 19, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.03
Real-time Price: $6.08 info
Change: -$1.94 (-24%) info
Market Cap: $6.404B info
IBRX
May 18, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.03
Real-time Price: $6.08 info
Change: -$1.95 (-24%) info
Market Cap: $6.404B info
IBRX
May 18, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.01
Real-time Price: $6.08 info
Change: -$1.92 (-24%) info
Market Cap: $6.404B info
IBRX
May 07, 2026, 7:37 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.09
Real-time Price: $6.08 info
Change: -$2.01 (-25%) info
Market Cap: $6.404B info
IBRX
May 07, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.05
Real-time Price: $6.08 info
Change: -$1.97 (-24%) info
Market Cap: $6.404B info
IBRX
Apr 29, 2026, 7:48 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $6.08 info
Change: -$0.9164 (-13%) info
Market Cap: $6.404B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets